International Journal of Colorectal Disease

, Volume 22, Issue 7, pp 827–831 | Cite as

Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer

  • Dujo Kovačevi
  • Zdenko Sonicki
  • Zvonko Kusi
  • Ante Bolanča
  • Goran Grubiši
  • Maja Lukač
  • Josip Lukač
Original Article

Abstract

Background and aim

Soluble c-erbB-2 oncoprotein has been proven as a useful marker in the management of breast cancer patients, but its value in diagnostics and follow-up of colorectal cancer patients remains controversial. The aim of this study was to evaluate the usefulness of serum c-erbB-2 monitoring in diagnostics and prediction of disease outcome in rectal cancer patients.

Materials and methods

Serum samples from 88 patients with rectal adenocarcinoma before surgery and from 41 healthy controls were tested for the presence of c-erbB-2 oncoprotein by ELISA, and the patients were followed up for at least 5 years after the surgery.

Results

Preoperative serum c-erbB-2 levels were significantly higher in stage IV patients than in healthy controls (P<0.001) and did not show correlation with preoperative CEA levels. Elevated preoperative serum c-erbB-2 levels showed relatively high specificity (88%) and low sensitivity (44%) in the diagnosis of rectal cancer. Elevated preoperative oncoprotein levels were predictive neither for overall survival nor for development of local recurrence/distant metastases.

Conclusion

Although preoperative serum c-erbB-2 levels were significantly higher in rectal cancer patients than in healthy controls, the soluble c-erbB-2 does not seem to be useful in the diagnosis of rectal cancer due to its low sensitivity. Preoperative serum levels of this oncoprotein were predictive neither for overall survival nor for local recurrence/distant metastases in rectal cancer patients.

Keywords

Rectal cancer Soluble c-erbB-2/HER-2/neu Tumor markers Follow-up 

References

  1. 1.
    Zabrecky JR, Lam T, McKenzie SJ, Carney W (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cell, SK-BR-3. J Biol Chem 266:1716–1720PubMedGoogle Scholar
  2. 2.
    Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton B, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A (1992) Elevated soluble c-erbB-2 antigen levels in the sera and effusions of a proportion of breast cancer patients. J Clin Oncol 10:1436–1443PubMedGoogle Scholar
  3. 3.
    Narita T, Funahashi H, Satoh Y, Takagi H (1992) C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24:97–102PubMedCrossRefGoogle Scholar
  4. 4.
    Luo JC, Yu MW, Chen CJ, Santella RW, Carney WP, Brandt-Rauf PW (1993) Serum c-erbB-2 oncopeptide in hepatocellular carcinogenesis. Med Sci Res 21:305–307Google Scholar
  5. 5.
    Yonemura Y, Nakai Y, Takamura H, Kaji M, Ninomiya i, Tsugawa K, Sugiyama K, Fujimura T, Miyazaki I, Endou Y, Tanaka M, Sasaki T, Hashimoto T (1993) Serum c-erbB-2 protein for the diagnosis of gastric cancer. Int J Oncol 3:325–329Google Scholar
  6. 6.
    Marx D, fattahi-Meibodi A, Kudelka R, Uebel T, Kuhn W, Meden H (1998) Detection of p100 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma. Anticancer Res 18:2891–2894PubMedGoogle Scholar
  7. 7.
    Kandl H, Seymour L, Bezwoda WR (1994) Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. BR J Cancer 70:739–742PubMedGoogle Scholar
  8. 8.
    Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A (1995) Elevated serum c-c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129–1135PubMedGoogle Scholar
  9. 9.
    Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wilmanns W (2002) Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumor Biol 23:70–75CrossRefGoogle Scholar
  10. 10.
    Vogel W, Kath R, Kosmehl H, Olschowsky E, Hoffken K (1996) The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. J Cancer Res Clin Oncol 122:118–121PubMedCrossRefGoogle Scholar
  11. 11.
    Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, Ballesta AM (1997) Serum levels of c-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumor Biol 18:188–196CrossRefGoogle Scholar
  12. 12.
    Lukač J, Kovačevi D, Krušlin B, Spaventi R, Ferenči, Belicza M, DeSyo D, Kusi Z (1998) Relationship between natural killer (NK) cell activity and erbB-2 expression in colorectal cancer patients. Period Biol 100:537–539Google Scholar
  13. 13.
    Chamberlain NL, Ward RL, Hawkins NJ (1999) Clinicopathological significance of erbB-2 expression in colorectal carcinoma. Oncol Rep 6:527–531PubMedGoogle Scholar
  14. 14.
    Tsigris C, Karayiannakis AJ, Zbar A, Syrigos KN, Baibas N, Diamantis T, Alexiou D (2002) Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Lett 184:215–222PubMedCrossRefGoogle Scholar
  15. 15.
    Polychronidis AC, Tsaroucha AK, Anagnostoulis SK, Efstathiou EE, Georgiadis PG, Simopoulos CE (2003) Serum levels of c-erbB-2 correlate with advanced stage and liver metastasis in colorectal cancer. Folia Med (Plovdiv) 45:12–16Google Scholar
  16. 16.
    Colon and rectum (1997) In: American Joint Committee on Cancer: AJCC cancer staging manual, 5th edn. Lippincott–Raven, Philadelphia, pp 83–90Google Scholar
  17. 17.
    World Medical Association. Declaration of Helsinki. Available at: http://www.wma.net/e/policy/b3.htm

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Dujo Kovačevi
    • 1
  • Zdenko Sonicki
    • 4
  • Zvonko Kusi
    • 2
  • Ante Bolanča
    • 2
  • Goran Grubiši
    • 3
  • Maja Lukač
    • 2
  • Josip Lukač
    • 2
  1. 1.Department of SurgerySisters of Charity University HospitalZagrebCroatia
  2. 2.Department of Oncology and Nuclear MedicineSisters of Charity University HospitalZagrebCroatia
  3. 3.Department of Obstetrics and GynecologySisters of Charity University HospitalZagrebCroatia
  4. 4.School of Public HealthZagrebCroatia

Personalised recommendations